Source comparison
MK-677 Osteoporosis: Treatment Comparison
Understanding where MK-677 fits requires comparing its mechanism and evidence base against established osteoporosis therapies. This table contrasts MK-677 with bisphosphonates, denosumab, and teriparatide. The three dominant drug classes in current practice. M
This comparison does not assign a generated winner or score.
- Understanding where MK-677 fits requires comparing its mechanism and evidence base against established osteoporosis therapies. This table contrasts MK-677 with bisphosphonates, denosumab, and teriparatide. The three dominant drug classes in current practice.
- MK-677 (ibutamoren)
- Growth hormone secretagogue. Stimulates pituitary GH release, elevates IGF-1, activates osteoblast differentiation and bone formation
- No Phase 3 fracture endpoint trials completed. Marker studies show increased bone turnover and formation markers but inconsistent BMD gains at 12 months.
- Oral, daily (25mg typical research dose)
- Investigational. Longest published trial 24 months
- Mechanistically sound anabolic approach with confirmed GH axis activation, but lacks the clinical fracture data required for standard-of-care osteoporosis treatment. Best suited for research settings or adjunct exploration in refractory cases.
- Bisphosphonates (alendronate, risedronate, zoledronic acid)
- Inhibit osteoclast-mediated bone resorption by binding hydroxyapatite and inducing osteoclast apoptosis
- 40–50% vertebral fracture reduction, 20–30% hip fracture reduction demonstrated in multiple Phase 3 trials (FIT, HORIZON, VERT)
- Oral weekly/monthly or IV annually
- 3–5 years typical, up to 10 years in high-risk patients
- Gold standard anti-resorptive therapy with the strongest long-term fracture data. However, suppresses remodeling without stimulating formation. BMD gains plateau after 3–5 years.
- Denosumab (Prolia)
- Monoclonal antibody inhibiting RANK-ligand, preventing osteoclast activation
- 68% vertebral fracture reduction, 40% hip fracture reduction (FREEDOM trial, 7,808 participants)
- Subcutaneous injection every 6 months
- Indefinite. Discontinuation causes rapid bone loss and rebound fracture risk
- Most potent anti-resorptive available with rapid BMD gains. Major drawback: rebound resorption upon cessation requires transition to bisphosphonate, complicating long-term management.
- Teriparatide (Forteo). Recombinant PTH(1-34)
- Anabolic agent. Intermittent PTH exposure stimulates osteoblast activity and bone formation
- 65% vertebral fracture reduction, 53% non-vertebral fracture reduction (Fracture Prevention Trial)
- Daily subcutaneous injection
- Maximum 24 months lifetime use (FDA black box: osteosarcoma risk in rat models)
- Only proven anabolic with fracture data. Expensive ($1,500–2,000/month), limited duration, requires follow-on anti-resorptive to maintain gains. Reserved for severe osteoporosis or bisphosphonate failures.
- The comparison clarifies MK-677's position: it shares teriparatide's anabolic mechanism (stimulating formation rather than just blocking resorption) but without the clinical trial infrastructure proving fracture benefit. Bisphosphonates and denosumab dominate because they work, they're proven, and insurers cover them. MK-677 remains an investigational tool until someone funds the multi-year, multi-thousand-participant trial required to answer the fracture question definitively.